Pa faint o fewnanadlyddion asthma aerosol sydd wedi cael eu rhagnodi gan GIG Cymru ar gyfer y flwyddyn ariannol bresennol; a phob un o'r pum mlynedd ariannol ddiwethaf, wedi'u dadansoddi yn ôl bwrdd iechyd?
Table 1. Inhaler quantity number by health board in Wales for financial years 2017/2018 to 2022/2023 (incomplete)
|
Health Board |
|
2017/2018 |
2018/2019 |
2019/2020 |
2020/2021 |
2021/2022 |
2022/2023 (April to August) |
|
Aneurin Bevan |
MDI quantity |
560,140 |
558,102 |
627,537 |
636,256 |
612,383 |
283,320 |
|
|
Total quantity |
855,805 |
841,621 |
937,417 |
944,498 |
905,800 |
425,127 |
|
|
% of Total |
65.5% |
66.3% |
66.9% |
67.4% |
67.6% |
66.6% |
|
Betsi Cadwaladr |
MDI quantity |
760,656 |
759,632 |
869,707 |
891,353 |
869,202 |
401,251 |
|
|
Total quantity |
1,019,202 |
1,019,568 |
1,162,798 |
1,183,903 |
1,147,696 |
538,035 |
|
|
% of Total |
74.6% |
74.5% |
74.8% |
75.3% |
75.7% |
74.6% |
|
Cardiff And Vale |
MDI quantity |
369,620 |
359,195 |
407,782 |
412,755 |
397,441 |
177,383 |
|
|
Total quantity |
553,533 |
549,546 |
629,572 |
636,833 |
614,829 |
284,257 |
|
|
% of Total |
66.8% |
65.4% |
64.8% |
64.8% |
64.6% |
62.4% |
|
Cwm Taf Morgannwg |
MDI quantity |
481,851 |
479,688 |
543,849 |
554,522 |
534,677 |
244,876 |
|
|
Total quantity |
773,488 |
764,106 |
854,916 |
856,691 |
812,217 |
373,645 |
|
|
% of Total |
62.3% |
62.8% |
63.6% |
64.7% |
65.8% |
65.5% |
|
Hywel Dda |
MDI quantity |
370,146 |
365,023 |
406,945 |
402,848 |
378,471 |
172,145 |
|
|
Total quantity |
555,413 |
550,968 |
616,420 |
612,643 |
581,666 |
269,699 |
|
|
% of Total |
66.6% |
66.3% |
66.0% |
65.8% |
65.1% |
63.8% |
|
Powys |
MDI quantity |
130,754 |
132,612 |
152,767 |
159,802 |
152,986 |
70,007 |
|
|
Total quantity |
183,664 |
183,206 |
207,871 |
216,003 |
206,478 |
97,049 |
|
|
% of Total |
71.2% |
72.4% |
73.5% |
74.0% |
74.1% |
72.1% |
|
Swansea Bay |
MDI quantity |
395,710 |
393,772 |
449,990 |
470,535 |
453,776 |
208,923 |
|
|
Total quantity |
567,248 |
566,020 |
643,989 |
663,888 |
634,952 |
292,595 |
|
|
% of Total |
69.8% |
69.6% |
69.9% |
70.9% |
71.5% |
71.4% |
|
Wales |
MDI quantity |
3,068,877 |
3,048,024 |
3,458,577 |
3,528,071 |
3,398,936 |
1,557,905 |
|
|
Total quantity |
4,508,352 |
4,475,036 |
5,052,983 |
5,114,459 |
4,903,638 |
2,280,406 |
|
|
% of Total |
68.1% |
68.1% |
68.4% |
69.0% |
69.3% |
68.3% |
Please note:
MDI are metered dose inhalers; these are sometimes referred to as the aerosol type. Total is made up of MDIs, plus DPIs (dry powder inhalers) and SMIs (soft mist inhalers).
Numbers presented are for primary care items only i.e. do not include secondary care data.
The NHS Wales Decarbonisation Strategic Delivery Plan (gov.wales) outlines the key actions identified to help NHS Wales reach the ambitious target of net zero by 2030. One target is to shift away from MDI inhalers (or aerosol type inhalers) so that 80% of total inhalers prescribed in Wales are those with a lower Global Warming Potential (GWP).
I expect doctors in primary care to prescribe medication and devices using clinical judgement, taking account of national guidance.
All Wales adult asthma management and prescribing guideline
This guideline aims to reduce variation in inhaler prescribing in the management of adult asthma.
All Wales COPD management and prescribing guideline
This guideline aims to reduce variation in inhaler prescribing in the management of chronic obstructive pulmonarydisease (COPD).
GPs in Wales have taken part in a Quality Improvement (QI) project linked to inhaler prescribing during 2021/22, with the aim of:
- optimising asthma and COPD patient care;
- using dry powder inhalers or soft mist inhalers as first-line treatment options where clinically appropriate;
- if metered dose inhalers are needed, then using a brand and dosage regime with care to minimise carbon footprint.
Guidance for a phase 2 QI project linked to decarbonisation and All Wales Medicines Strategy Group Key Prescribing Indicators for 2022/23 https://awttc.nhs.wales/files/national-prescribing-indicators/national-prescribing-indicators-2022-2023-v3-pdf/ , will be made available to GP practices in the coming weeks.
GP practices are supported by pharmacy teams across primary care, with many health boards having respiratory leads working with practice teams and decarbonisation champions within community pharmacy.